+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 41 Actively Recruiting clinical trials

E

Actively Recruiting

Researchers are investigating new treatment options for people with locally advanced or metastatic colorectal cancer mCRC that cannot be removed by surgery and has a specific gene mutation called KRAS G12C. The study aims to evaluate the safety and tolerance of combining calderasib, cetuximab, and mFOLFOX6 chemotherapy compared to the standard treatment of mFOLFOX6 with or without bevacizumab. This research is a phase 3 clinical trial focused on improving outcomes for this specific patient group. Participants will be assigned to one of two groups. One group receives calderasib tablets orally, cetuximab every two weeks, and mFOLFOX6 chemotherapy including oxaliplatin, leucovorin or levofolinate calcium, and 5-fluorouracil every two weeks. The other group receives mFOLFOX6 chemotherapy with or without bevacizumab or a bevacizumab biosimilar, also administered every two weeks. Treatment continues until doctors decide to stop based on specific criteria. During the study, participants will be closely monitored for side effects and treatment tolerability, with evaluations lasting up to about 44 months in the first part and up to 5 years in the second part. Researchers will collect data on progression-free survival, response rates, overall survival, and quality of life using various questionnaires. Safety assessments and tracking of any adverse events will be conducted regularly throughout the study.

Age: 18Years +All GendersPhase 3
245 locations
E

Actively Recruiting

Researchers are investigating new treatments for neovascular age-related macular degeneration NVAMD, a condition that affects the eye and vision. This trial aims to compare a new medicine called tiespectus also known as MK-8748 or EYE201 with the standard treatment aflibercept to see if tiespectus works as well for people with NVAMD. The study is a randomized, double-masked, pivotal phase 23 trial focusing on treatment effectiveness and safety. Participants will be assigned to one of three groups one receiving a low dose of tiespectus, another receiving a high dose of tiespectus, and a third group receiving aflibercept. In the tiespectus groups, participants will get three initial injections every four weeks, followed by injections every eight weeks until week 48. After week 48, treatment intervals will be personalized based on individual responses, continuing up to week 92. The aflibercept group also receives three initial injections followed by injections every eight weeks until week 92. Throughout the study, participants will have their vision assessed using a standard eye chart to measure changes in best-corrected visual acuity BCVA from the start through one year. Additional measures include eye imaging to assess retinal thickness and monitoring for any side effects or adverse events up to approximately 96 weeks. The trial will last until June 2028, with ongoing monitoring and follow-up visits to evaluate the safety and effectiveness of the treatments.

Age: 50Years +All GendersPhase 2Phase 3
132 locations
E

Actively Recruiting

Researchers are evaluating BRX011, an oral medication taken once daily, for adults with geographic atrophy secondary to age-related macular degeneration. This phase 12 study aims to assess both the safety and effectiveness of BRX011 compared to a placebo over nearly two years. The study focuses on how well the treatment slows the progression of geographic atrophy. Participants will be randomly assigned to receive either BRX011 capsules or placebo capsules daily. The study lasts 96 weeks and includes multiple visits to monitor health and treatment response. Safety is closely monitored with regular checks including vital signs, lab tests, eye exams, and imaging to detect any adverse effects. During the study, participants will undergo evaluations such as visual acuity testing and imaging of the eye to measure changes in geographic atrophy area. Researchers will track the annual rate of change in the square root of the geographic atrophy area as the primary outcome. Secondary measures include changes in vision under low light and best-corrected visual acuity. Participant well-being is monitored throughout, and the study is sponsored by Biojiva LLC.

Age: 55Years +All GendersPhase 1Phase 2
17 locations
P

Actively Recruiting

Researchers are evaluating the safety and effectiveness of KarXT combined with KarX-EC in adults aged 55 to 90 who experience agitation related to Alzheimers Disease. This Phase 3, randomized, double-blind, placebo-controlled study aims to better understand how these treatments may impact agitation symptoms in this population. The study is sponsored by Bristol-Myers Squibb and focuses on agitation as a complication of Alzheimers disease. Participants will be randomly assigned to receive either the combination of XanomelineTrospium Chloride Capsule and Xanomeline Enteric Capsule or a placebo. The treatments are given at specified doses on designated days. The study uses a parallel group design to compare these two options over a treatment period lasting up to 14 weeks. During the study, participants and their caregivers will attend regular visits for assessments including agitation severity using the Cohen-Mansfield Agitation Inventory-International Psychogeriatric Association total score, clinical global impressions, and other neuropsychiatric evaluations. Safety will be closely monitored through adverse event reporting and various clinical tests, including movement scales, vital signs, lab tests, ECGs, and assessments for suicidal thoughts. Caregivers will help oversee medication compliance and report on participant status. The entire study period extends through Week 18 for safety follow-up.

Age: 55Years - 90YearsAll GendersPhase 3
143 locations
E

Actively Recruiting

Researchers are evaluating the effectiveness and safety of Datopotamab Deruxtecan Dato-DXd with or without durvalumab compared to chemotherapy chosen by doctors combined with pembrolizumab in people with PD-L1 positive locally recurrent inoperable or metastatic triple-negative breast cancer TNBC. This Phase III international study aims to see if Dato-DXd plus durvalumab can help patients live longer without their cancer worsening or improve overall survival, while also assessing impacts on quality of life. Participants are randomly assigned to one of three groups Dato-DXd with durvalumab, a chemotherapy option paclitaxel, nab-paclitaxel, or gemcitabine plus carboplatin combined with pembrolizumab, or Dato-DXd alone. All study drugs are given by intravenous infusion. The study will monitor patients for disease progression and response, with treatments and evaluations continuing for up to about 33 months. During the study, participants will undergo regular assessments including tumor measurements by imaging using RECIST 1.1 criteria, survival tracking, and quality of life evaluations focused on symptoms like breast and arm pain and physical functioning. Safety and drug effects will also be closely monitored throughout treatment and follow-up. The total study participation may last several years, with some outcomes measured up to 64 months from randomization.

Age: 18Years +All GendersPhase 3
318 locations
R

Actively Recruiting

The trial investigates treatments for adults with KRASNRAS and BRAF wild-type recurrent, unresectable, or metastatic colorectal cancer who have previously undergone chemotherapy. It compares how long participants live without disease progression and overall survival when treated with two different combinations of chemotherapy and targeted biological agents. This phase 3 study explores differences in outcomes between the use of amivantamab plus FOLFIRI chemotherapy and cetuximab or bevacizumab plus FOLFIRI chemotherapy. Participants are randomly assigned to one of two groups. One group receives amivantamab together with FOLFIRI, a chemotherapy regimen including 5-fluorouracil, leucovorin calcium or levoleucovorin, and irinotecan. The other group receives either cetuximab or bevacizumab with the same FOLFIRI chemotherapy. Treatments are given in 28-day cycles and continue until disease progression is observed on scans or other stopping criteria are met. During the study, participants undergo regular monitoring including radiographic scans to assess disease status and progression-free survival for up to 2 years and overall survival for over 4 years. Researchers also evaluate tumor response rates, duration and time to response, quality of life through questionnaires, side effects, and laboratory tests. The total study duration may extend up to more than 4 years to thoroughly assess treatment outcomes and safety.

Age: 18Years +All GendersPhase 3
251 locations
R

Actively Recruiting

This clinical trial is designed to compare the duration participants remain free of disease progression when treated with two different combinations of therapies for adults with KRASNRAS and BRAF wild-type unresectable or metastatic left-sided colorectal cancer. The study focuses on how amivantamab combined with chemotherapy compares to cetuximab combined with chemotherapy in treating this specific cancer type. Participants will be divided into two groups. One group receives amivantamab combined with chemotherapy, either mFOLFOX6 containing 5-fluorouracil, leucovorin calcium or levoleucovorin, and oxaliplatin or FOLFIRI containing 5-fluorouracil, leucovorin calcium or levoleucovorin, and irinotecan hydrochloride. The other group receives cetuximab combined with the same chemotherapy options. Treatments are given in 28-day cycles and continue until the cancer progresses or other reasons require stopping the treatment. Throughout the study, participants will undergo regular evaluations to monitor how long they remain without disease progression, assessed by independent review and investigators. Other assessments include overall survival, response rates, duration of response, quality of life questionnaires, and safety monitoring up to several years. The study spans several years, with primary outcomes measured up to over four years and additional follow-up extending beyond seven years to gather comprehensive data on treatment effects and patient well-being.

Age: 18Years +All GendersPhase 3
239 locations
S

Actively Recruiting

Researchers are evaluating the anti-tumor activity and safety of amivantamab, alone and combined with standard chemotherapy, in participants with advanced or metastatic colorectal cancer. This study focuses on different groups based on prior treatments and tumor characteristics, aiming to find effective dosing for amivantamab combined with standard chemotherapy. The study includes participants with specific genetic tumor profiles and performance status, assessing treatment effects in various cohorts. Participants receive intravenous infusions of amivantamab alone or with chemotherapy regimens such as mFOLFOX6 or FOLFIRI, depending on their cohort and prior treatment history. The treatment cycles last 28 days and continue until the end of treatment visit, which occurs up to 30 days after discontinuation. Dose levels and schedules vary by cohort, with some receiving monotherapy and others combination therapies at doses determined in earlier phases. Throughout the study, participants undergo physical exams, performance status assessments, laboratory tests, vital sign monitoring, and adverse event tracking. Tumor response and disease control are measured using standard criteria over up to four years and three months. Biopsies are required for certain cohorts to assess tumor characteristics. Safety and treatment effects are closely monitored during and after treatment to evaluate amivantamabs impact.

Age: 18Years +All GendersPhase 1Phase 2
53 locations
C

Actively Recruiting

This trial is designed to evaluate the safety, tolerability, and effectiveness of the combination of nemtabrutinib plus venetoclax compared to venetoclax plus rituximab in adults with relapsed or refractory chronic lymphocytic leukemiasmall lymphocytic lymphoma RR CLLSLL. The study aims to confirm the dose of nemtabrutinib and assess progression-free survival as the primary outcome, using established criteria and independent review. Participants are assigned to one of two treatment groups. One group receives daily oral nemtabrutinib starting on the first day of cycle 1 and venetoclax starting on the first day of cycle 2, continuing up to two years or until disease progression or discontinuation. The other group receives daily oral venetoclax starting on cycle 1 day 1, plus intravenous rituximab infusion for six cycles. Each treatment cycle lasts four weeks. During the study, participants undergo regular monitoring for dose-limiting toxicities, adverse events, and treatment discontinuations. Assessments include progression-free survival, minimal residual disease in bone marrow, overall survival, response rates, and duration of response. The study duration spans several years, with safety and efficacy monitored throughout and follow-up extending beyond treatment completion to gather comprehensive data on participant outcomes.

Age: 18Years +All GendersPhase 3
99 locations
C

Actively Recruiting

Researchers are evaluating sacituzumab tirumotecan alone or combined with pembrolizumab to treat people with triple-negative breast cancer TNBC that is locally recurrent, unresectable, or metastatic and expresses PD-L1 at a combined positive score less than 10. The study aims to find out if these treatments help people live longer overall or delay cancer growth compared to chemotherapy chosen by their physician. This is a phase 3 randomized trial focused on treatment effectiveness and safety. Participants are randomly assigned to one of three groups sacituzumab tirumotecan given intravenously every two weeks sacituzumab tirumotecan every two weeks plus pembrolizumab every six weeks for up to about two years or physicians choice chemotherapy including options like paclitaxel, nab-paclitaxel, gemcitabine plus carboplatin with varying schedules. Pre-medications such as antihistamines, acetaminophen, and steroids are given before sacituzumab tirumotecan infusions to reduce side effects. During the study, participants receive assigned treatments until disease progression, toxicity, or discontinuation. Researchers monitor progression-free survival and overall survival up to about 39 and 61 months respectively. They also assess response rates, duration of response, quality of life changes using questionnaires, and record adverse events over the study period. The trial follows participants for extended periods to evaluate long-term outcomes and safety.

Age: 18Years +All GendersPhase 3
283 locations

1-10 of 41

1